chlorisondamine has been researched along with Atherosclerotic Parkinsonism in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abin-Carriquiry, JA; Costa, G; Dajas, F | 1 |
1 other study(ies) available for chlorisondamine and Atherosclerotic Parkinsonism
Article | Year |
---|---|
Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorisondamine; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Injections, Subcutaneous; Male; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2001 |